Home>News> Bristol Myers’ Opdivo clears signs of lung cancer in first-in-class pre-surgery win

Bristol Myers’ Opdivo clears signs of lung cancer in first-in-class pre-surgery win

Bristol Myers Squibb’s Opdivo may not be the most popular immunotherapy for treating metastatic non-small cell lung cancer, but it’s now the first to report positive late-stage clinical results in resectable cases before surgery.
 
Adding Opdivo to standard chemotherapy before surgery helped significantly more non-small cell lung cancer patients show no evidence of cancer cells in their resected tissue compared with chemo alone, BMS said Wednesday.

Tags: